Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Major indices closed lower on Monday after Donald Trump slapped several key trading partners with tariffs, leading to fears ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.

This was the stock's second consecutive day of gains.

AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...